Fragile X

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares were advancing Tuesday after the company notched a new U.S. patent for its cannabidiol product candidate, ZYN002 transdermal gel. What Happened The biotech, which develops transdermal cannabinoid therapies for rare and near-rare neuropsychiatric...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) announced Thursday its Phase 2 trial for ZYN002 in Fragile X syndrome found sustained improvements in patients’ core behavioral symptoms. The drug was well tolerated with no serious adverse events. Why It’s Important The candidate is the most...

The Street reacted to Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)’s positive Fragile X trial results with marked ambivalence. Investors propelled the stock 76 percent higher even as biotech and behavioral experts published critical reviews. Two analysts assigned Hold ratings, but Piper Jaffray...

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a nano-cap specialty pharmaceutical company that specializes in transdermal synthetic cannabinoid treatments for patients with high unmet needs, reported its second-quarter results Tuesday and also provided several key updates to ongoing...